n-myristoyltransferase inhibitors new leads treat sleeping sickness 
african sleeping sickness human african trypanosomiasis caused trypanosoma brucei spp responsible similar deaths year available treatments disease poor unacceptable efficacy safety profiles particularly late stage disease parasite infected central nervous system report validation molecular target discovery associated lead compounds potential address lack suitable treatments inhibition target-t brucei n-myristoyltransferase-leads rapid killing trypanosomes vitro vivo cures trypanosomiasis mice high-affinity inhibitors bind peptide substrate pocket enzyme inhibit protein n-myristoylation trypanosomes compounds identified promising pharmaceutical properties represent opportunity develop oral drugs treat devastating disease studies validate t brucei n-myristoyltransferase promising therapeutic target human african trypanosomiasis 
